Case Report| Volume 235, P13-17, June 2019

A novel CHEK2 variant identified by next generation sequencing in an Indian family with hereditary breast cancer syndrome


      Genetic variations in CHEK2 (checkpoint kinase 2) gene have been associated with hereditary predisposition to various cancers including breast and ovarian cancer. CHEK2 tumor suppressor gene encodes for a checkpoint kinase that responds to breaks in DNA, regulates DNA repair and cellular proliferation. We report a BRCA negative family with multiple affected women having breast cancer, with a novel, missense, likely pathogenic variant in the CHEK2 gene (c.1376T>G; p.Ile459Ser) that segregated with subjects with breast cancer. This case provides insight into the role of the CHEK2 gene in causing breast cancer susceptibility in families and supports the use of multigene panel testing in cases with hereditary predisposition to breast cancer.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cancer Genetics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Bradbury AR
        • Olopade OI
        Genetic susceptibility to breast cancer.
        Rev Endocr Metab Dis. 2007; 8: 255-267
        • Bartek J
        • Lukas J
        CHK1 and CHK2 kinases in checkpoint control and cancer.
        Cancer Cell. 2003; 3: 421-429
        • Narod SA
        Testing for CHEK2 in the cancer genetics clinic: ready for prime time?.
        Clin Genet. 2010; 78: 1-7
        • Liang M
        • Zhang Y
        • Sun C
        • Rizeq FK
        • Min M
        • Shi T
        • et al.
        Association between CHEK2*1100°C and breast cancer: a systematic review and meta-analysis.
        Mol Diagn Ther. 2018; ([Epub ahead of print])
        • Fan Z
        • Ouyang T
        • Li J
        • Wang T
        • Fan Z
        • Fan T
        • et al.
        Identification and analysis of CHEK2 germline mutations in Chinese BRCA1/2-negative breast cancer patients.
        Breast Cancer Res Treat. 2018; 169: 59-67
        • Apostolou P
        • Fostira F
        • Mollaki V
        • Delimitsou A
        • Vlassi M
        • Pentheroudakis G
        • et al.
        Characterization and prevalence of two novel CHEK2 large deletions in Greek breast cancer patients.
        J Hum Genet. 2018; 63: 877-886
        • Habyarimana T
        • Attaleb M
        • Mugenzi P
        • Mazarati JB
        • Bakri Y
        • El Mzibri M
        CHEK2 germ line mutations are lacking among familial and sporadic breast cancer patients in Rwanda.
        Asian Pac J Cancer Prev. 2018; 19: 375-379
        • Apostolou P
        • Papasotiriou I
        Current perspectives on CHEK2 mutations in breast cancer.
        Breast Cancer (Dove Med Press). 2017; 9: 331-335
        • Rajkumar T
        • Soumittra N
        • Nancy NK
        • Swaminathan R
        • Sridevi V
        • Shanta V
        BRCA1, BRCA2 and CHEK2 (1100°C) germline mutations in hereditary breast and ovarian cancer families in South India.
        Asian Pac J Cancer Prev. 2003; 4: 203-208
        • Soumittra N
        • Meenakumari B
        • Parija T
        • Sridevi V
        • Nancy KN
        • Swaminathan R
        • et al.
        Molecular genetics analysis of hereditary breast and ovarian cancer patients in India.
        Hered Cancer Clin Pract. 2009; 7: 13
        • Schwarz JM
        • Cooper DN
        • Schuelke M
        • Seelow D
        MutationTaster2: mutation prediction for the deep-sequencing age.
        Nat Methods. 2014; 11: 361-366
        • Adzhubei IA
        • Schmidt S
        • Peshkin L
        • Ramensky VE
        • Gerasimova A
        • Bork P
        • et al.
        A method and server for predicting damaging missense mutations.
        Nat Methods. 2010; 7: 248-249
        • Reva B
        • Antipin Y
        • Sander C
        Predicting the functional impact of protein mutations: application to cancer genomics.
        Nucl Acids Res. 2011; 39: e118
        • Choi Y
        • Chan AP
        PROVEAN web server: a tool to predict the functional effect of amino acid substitutions and indels.
        Bioinformatics. 2015; 31: 2745-2747
        • Cybulski C
        • Wokołorczyk D
        • Jakubowska A
        • Huzarski T
        • Byrski T
        • Gronwald J
        • et al.
        Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer.
        J Clin Oncol. 2011; 29: 3747-3752
        • Weischer M
        • Bojesen SE
        • Ellervik C
        • Tybjaerg-Hansen A
        • Nordestgaard BG
        CHEK2*1100°C genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls.
        J Clin Oncol. 2008; 26: 542-548
        • Wang N
        • Ding H
        • Liu C
        • Li X
        • Wei L
        • Yu J
        • et al.
        A novel recurrent CHEK2 Y390C mutation identified in high-risk Chinese breast cancer patients impairs its activity and is associated with increased breast cancer risk.
        Oncogene. 2015; 34: 5198-5205
        • Bell DW
        • Kim SH
        • Godwin AK
        • Schiripo TA
        • Harris PL
        • Haserlat SM
        • et al.
        Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts.
        Int J Cancer. 2007; 121: 2661-2667
        • Rajkumar T
        • Meenakumari B
        • Mani S
        • Sridevi V
        • Sundersingh S
        Targeted resequencing of 30 genes improves the detection of deleterious mutations in South Indian women with breast and/or ovarian cancers.
        Asian Pac J Cancer Prev. 2015; 16: 5211-5217
        • Mannan AU
        • Singh J
        • Lakshmikeshava R
        • Thota N
        • Singh S.
        • Sowmya T.S.
        • et al.
        Detection of high frequency of mutations in a breast and/or ovarian cancer cohort: implications of embracing a multi-gene panel in molecular diagnosis in India.
        J Hum Genet. 2016; 61: 515-522
        • Singh J
        • Thota N
        • Singh S
        • Padhi S
        • Mohan P
        • Deshwal S
        • et al.
        Screening of over 1000 Indian patients with breast and/or ovarian cancer with a multi-gene panel: prevalence of BRCA1/2 and non-BRCA mutations.
        Breast Cancer Res Treat. 2018; 170: 189-196
        • Gronwald J
        • Cybulski C
        • Piesiak W
        • Suchy J
        • Huzarski T
        • Byrski T
        • et al.
        Cancer risks in first-degree relatives of CHEK2 mutation carriers: effects of mutation type and cancer site in proband.
        Br J Cancer. 2009; 100: 1508-1512